Trials / Terminated
TerminatedNCT04700280
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Primary Sjögren's Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3970 | GLPG3970 film-coated tablet. |
| DRUG | Placebo | Placebo film-coated tablet. |
Timeline
- Start date
- 2021-01-28
- Primary completion
- 2021-10-28
- Completion
- 2021-12-27
- First posted
- 2021-01-07
- Last updated
- 2023-09-18
- Results posted
- 2023-09-18
Locations
10 sites across 5 countries: Germany, Greece, Hungary, Poland, Ukraine
Source: ClinicalTrials.gov record NCT04700280. Inclusion in this directory is not an endorsement.